Search

everythinglearnresearchcommunity

for

Search:↓

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

Testosterone therapy increases bone density in older men with low testosterone levels.

Higher BMI and lower testosterone are linked to more aggressive prostate cancer.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

Androgens increase cervical cancer risk and affect its development.

Cimicifuga racemosa extract may help prevent and treat prostate issues by inhibiting 5α-reductase.

Metformin may lower PSA levels, possibly affecting prostate cancer development.

Wnt-activating drugs generally do not increase cancer risk.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

Targeting ACE2 and TMPRSS2 may help prevent or treat COVID-19 in cancer patients.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

The document suggests a possible link between FAM111B gene mutations and increased cancer risk, particularly pancreatic cancer.

Finasteride lowers PSA levels and prostate size, requiring adjusted PSA interpretation for accurate cancer screening.

The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.

Using finasteride with TIP extends time off period for prostate cancer patients.

Early onset baldness in men may indicate a condition similar to PCOS, linked to heart disease, diabetes, and prostate issues.

Testosterone replacement therapy improves libido, mood, muscle strength, and bone density in men with Testosterone Deficiency Syndrome.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.

Shorter PSADT after prostate surgery is linked to higher risk of death.

The document concludes that understanding health requires considering evolutionary perspectives on reproductive fitness, and recognizing the complexity of factors like diet, testosterone, and sexual orientation.

Testosterone supplements can increase muscle mass and strength in older men with low levels, but long-term effects and risks need more research.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

Taking 5-α reductase inhibitors for prostate enlargement or hair loss does not significantly raise the risk of erectile dysfunction.

Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.

Oral contraceptives lower testosterone levels in women, especially those with certain genetic traits, and may be linked to increased breast cancer risk.

Hair dyes and perms can damage hair and scalp, but using interventions can reduce harm.

Some skin, hair, and nail supplements can be toxic, interact with medications, affect lab tests, and may increase cancer risk.

A new genetic region, 17q21.31, is linked to higher ovarian cancer risk.